



**ASX Announcement**

**22 February 2023**

## **Change of Company Secretary**

Atomo Diagnostics Limited (ASX: AT1) (**Atomo** or the **Company**) wishes to advise in accordance with ASX Listing Rule 3.16.1 that Ms Maria Clemente of BoardRoom Pty Limited has been appointed Company Secretary, with effect from 1 March 2023. For the purposes of ASX Listing Rule 12.6, Ms Clemente will also be the primary person responsible for communications between the Company and the ASX.

Mr Tharun Kuppanda of BoardRoom Pty Limited has notified the Board of his resignation as Company Secretary with effect from 1 March 2023. Atomo thanks Mr Kuppanda for his support of the Board during his time with the Company.

### **For more information:**

#### **John Kelly**

MD & CEO, Atomo Diagnostics Limited

[john.kelly@atomodiagnositics.com](mailto:john.kelly@atomodiagnositics.com)

+61 401 922 279

*This announcement was authorised by the Board of Atomo Diagnostics Limited.*

### **About Atomo**

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health.

See more at [www.atomodiagnositics.com](http://www.atomodiagnositics.com)